WHAT IS CLAIMED IS:

1. A method for treating a subject having a cancer, wherein the method comprises orally administering to the subject a pharmaceutical composition comprising a cytidine analog, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and the method optionally further comprises administering at least one additional therapeutic agent.

2. The method of claim 1, wherein the cancer is a relapsed or refractory solid tumor.

3. The method of claim 1 or 2, wherein the cancer is bladder cancer, ovarian cancer, lung cancer, pancreatic cancer, or colorectal cancer.

4. The method of any one of claims 1 to 3, wherein the additional therapeutic agent is an anti-cancer agent.

5. The method of claim 4, wherein the additional therapeutic agent is a platinum agent.

6. The method of claim 5, wherein the additional therapeutic agent is carboplatin.

7. The method of claim 4, wherein the additional therapeutic agent is a taxane.

8. The method of claim 7, wherein the additional therapeutic agent is paclitaxel.

9. The method of claim 7, wherein the additional therapeutic agent is paclitaxel protein-bound particles.

10. The method of claim 7, wherein the additional therapeutic agent is Abraxane.

11. The method of any one of claims 1 to 10, wherein the method comprises the sequential steps of:

(i) administering the cytidine analog to the subject for 1, 2, 3, 4, 5, 6, or 7 days; and

(ii) administering the additional therapeutic agent to the subject for one or more days.

12. The method of claim 11, wherein the additional therapeutic agent is administered parenterally.

13. The method of claim 11, wherein the additional therapeutic agent is administered orally.

14. The method of any one of claims 11 to 13, wherein step (ii) further comprises administering the cytidine analog orally for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days.

15. The method of any one of claims 11 to 13, wherein the method comprises the sequential steps of:

(i) administering the cytidine analog to the subject for 7 days;

(ii) administering the additional therapeutic agent to the subject for 1 day;

(iii) administering the cytidine analog to the subject for 6 days; and

(iv) after 7 days of resting period, repeat steps (i) to (iii).

16. The method of any one of claims 11 to 13, wherein the method comprises the sequential steps of:

(i) administering the cytidine analog to the subject for 7 days;

(ii) administering the cytidine analog and the additional therapeutic agent to the subject for 1 day;

(iii) administering the cytidine analog to the subject for 6 days; and

(iv) after 7 days of resting period, repeat steps (i) to (iii).

17. The method of any one of claims 11 to 13, wherein the method comprises the sequential steps of:

(i) administering the cytidine analog to the subject for 7 days;

(ii) administering the cytidine analog and the additional therapeutic agent to the subject for 1 day;

(iii) administering the cytidine analog to the subject for 6 days;

(iv) administering the additional therapeutic agent to the subject for 1 day; and

(v) after 6 days of resting period, repeat steps (i) to (iv).

18. The method of any one of claims 11 to 13, wherein the method comprises the sequential steps of:

(i) administering the cytidine analog to the subject for 7 days;

(ii) administering the cytidine analog and the additional therapeutic agent to the subject for 1 day;

(iii) administering the cytidine analog to the subject for 6 days;

(iv) administering the additional therapeutic agent to the subject for 1 day;

(v) after 6 days of resting period, administering the cytidine analog and the additional therapeutic agent to the subject for 1 day;

(vi) administering the cytidine analog to the subject for 6 days; and

(vii) repeat steps (ii) to (vi).

19. The method of any one of claims 1 to 10, wherein the method comprises administering the cytidine analog to the subject for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7 days, before administering the additional therapeutic agent to the subject.

20. The method of claim 19, wherein the additional therapeutic agent is administered parenterally for one or more days.

21. The method of claim 19, wherein the additional therapeutic agent is administered orally for one or more days.

22. The method of any one of claims 1 to 21, wherein the pharmaceutical composition comprising the cytidine analog is a tablet.

23. The method of any one of claims 1 to 21, wherein the pharmaceutical composition comprising the cytidine analog is a capsule.

24. The method of any one of claims 1 to 23, wherein the pharmaceutical composition comprises about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, or about 600 mg of the cytidine analog.

25. The method of claim 24 wherein the pharmaceutical composition comprises about 200 mg of the cytidine analog.

26. The method of claim 24, wherein the pharmaceutical composition comprises about 300 mg of the cytidine analog.

27. The method of any one of claims 1 to 26, wherein the subject is a human.

28. The method of any one of claims 1 to 27, wherein the cytidine analog is 5-azacytidine.

29. The method of any one of claims 1 to 27, wherein the cytidine analog is decitabine.

WHAT IS CLAIMED IS:

1. Use of a cytidine analog, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and optionally at least one additional therapeutic agent in the manufacture of a medicament for treating a subject having a cancer, wherein the cytidine analog, or a pharmaceutically acceptable salt, solvate, or hydrate thereof is to be administered orally.

2. The use of claim 1, wherein the cancer is a relapsed or refractory solid tumor.

3. The use of claim 1 or 2, wherein the cancer is bladder cancer, ovarian cancer, lung cancer, pancreatic cancer, or colorectal cancer.

4. The use of any one of claims 1 to 3, wherein the additional therapeutic agent is an anti-cancer agent.

5. The use of claim 4, wherein the additional therapeutic agent is a platinum agent.

6. The use of claim 5, wherein the additional therapeutic agent is carboplatin.

7. The use of claim 4, wherein the additional therapeutic agent is a taxane.

8. The use of claim 7, wherein the additional therapeutic agent is paclitaxel.

9. The use of claim 7, wherein the additional therapeutic agent is paclitaxel protein-bound particles.

10. The use of claim 7, wherein the additional therapeutic agent is Abraxane.

11. The use of any one of claims 1 to 10, wherein the use comprises the sequential steps of:

(i) administration of the cytidine analog to the subject for 1, 2, 3, 4, 5, 6, or 7 days; and

(ii) administration of the additional therapeutic agent to the subject for one or more days.

12. The use of claim 11, wherein the additional therapeutic agent is to be administered parenterally.

13. The use of claim 11, wherein the additional therapeutic agent is to be administered orally.

14. The use of any one of claims 11 to 13, wherein step (ii) further comprises the cytidine analog to be administered orally for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days.

15. The use of any one of claims 11 to 13, wherein the use comprises the sequential steps of:

(i) administration of the cytidine analog to the subject for 7 days;

(ii) administration of the additional therapeutic agent to the subject for 1 day;

(iii) administration of the cytidine analog to the subject for 6 days; and

(iv) after 7 days of resting period, repeat steps (i) to (iii).

16. The use of any one of claims 11 to 13, wherein the use comprises the sequential steps of:

(i) administration of the cytidine analog to the subject for 7 days;

(ii) administration of the cytidine analog and the additional therapeutic agent to the subject for 1 day;

(iii) administration of the cytidine analog to the subject for 6 days; and

(iv) after 7 days of resting period, repeat steps (i) to (iii).

17. The use of any one of claims 11 to 13, wherein the use comprises the sequential steps of:

(i) administration of the cytidine analog to the subject for 7 days;

(ii) administration of the cytidine analog and the additional therapeutic agent to the subject for 1 day;

(iii) administration of the cytidine analog to the subject for 6 days;

(iv) administration of the additional therapeutic agent to the subject for 1 day; and

(v) after 6 days of resting period, repeat steps (i) to (iv).

18. The use of any one of claims 11 to 13, wherein the use comprises the sequential steps of:

(i) administration of the cytidine analog to the subject for 7 days;

(ii) administration of the cytidine analog and the additional therapeutic agent to the subject for 1 day;

(iii) administration of the cytidine analog to the subject for 6 days;

(iv) administration of the additional therapeutic agent to the subject for 1 day;

(v) after 6 days of resting period, administering the cytidine analog and the additional therapeutic agent to the subject for 1 day;

(vi) administration of the cytidine analog to the subject for 6 days; and

(vii) repeat steps (ii) to (vi).

19. The use of any one of claims 1 to 10, wherein the use comprises administration of the cytidine analog to the subject for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7 days, before administration of the additional therapeutic agent to the subject.

20. The use of claim 19, wherein the additional therapeutic agent is to be administered parenterally for one or more days.

21. The use of claim 19, wherein the additional therapeutic agent is to be administered orally for one or more days.

22. The use of any one of claims 1 to 21, wherein the pharmaceutical composition comprising the cytidine analog is a tablet.

23. The use of any one of claims 1 to 21, wherein the pharmaceutical composition comprising the cytidine analog is a capsule.

24. The use of any one of claims 1 to 23, wherein the pharmaceutical composition comprises about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, or about 600 mg of the cytidine analog.

25. The use of claim 24 wherein the pharmaceutical composition comprises about 200 mg of the cytidine analog.

26. The use of claim 24, wherein the pharmaceutical composition comprises about 300 mg of the cytidine analog.

27. The use of any one of claims 1 to 26, wherein the subject is a human.

28. The use of any one of claims 1 to 27, wherein the cytidine analog is 5-azacytidine.

29. The use of any one of claims 1 to 27, wherein the cytidine analog is decitabine.